Trials / Completed
CompletedNCT05358886
A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 171 (actual)
- Sponsor
- Tetra Discovery Partners · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BPN14770/ zatolmilast | 25mg BID BPN14770 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2022-11-01
- Primary completion
- 2025-07-18
- Completion
- 2025-07-18
- First posted
- 2022-05-03
- Last updated
- 2025-07-23
Locations
17 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05358886. Inclusion in this directory is not an endorsement.